First, the clinical gold standard—quantitative analysis of PD-L1 expression in tumor tissue is constrained by tumor heterogeneity [15], post-translational modifications [16], and inconsistencies in detection antibodies and platforms [17]. The gene discussed is CD274; the disease is neoplasm.